Nabholtz Jean-Marc A, Reese David M, Lindsay Mary-Ann, Riva Alessandro
University of California, Los Angeles, Peter Ueberroth Building 3360B, 10945 Le Conte Avenue, Los Angeles, CA 90095-7077, USA.
Expert Rev Anticancer Ther. 2002 Apr;2(2):169-80. doi: 10.1586/14737140.2.2.169.
Despite more than four decades of effort, the improvement in survival in metastatic breast cancer has been modest. Recently, however, new drugs such as the taxanes have emerged as pivotal agents in the treatment of metastatic disease and they are now being investigated in the adjuvant setting. In addition, the introduction of molecularly targeted therapies such as trastuzumab provides a new paradigm for the development of biologic treatments. The incorporation of trastuzumab into new combination regimens based on potential molecular synergies is a focus of current research.
尽管经过了四十多年的努力，转移性乳腺癌患者的生存率改善仍较为有限。然而，近年来，紫杉烷类等新药已成为转移性疾病治疗的关键药物，目前正处于辅助治疗的研究阶段。此外，曲妥珠单抗等分子靶向治疗药物的出现为生物治疗的发展提供了新的模式。基于潜在分子协同作用将曲妥珠单抗纳入新的联合治疗方案是当前研究的重点。
